BFA
PRTK

BlackRock Fund Advisors’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History

BlackRock Fund Advisors’s Portfolio PRTK Stock Details PRTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		$13.9M Buy
901,143
+389,165
+76% +$5.05M ﹤0.01% 2390
2016
Q3 		$6.66M Buy
511,978
+138,559
+37% +$1.84M ﹤0.01% 2698
2016
Q2 		$5.19M Buy
373,419
+55,915
+18% +$823K ﹤0.01% 2778
2016
Q1 		$4.82M Sell
317,504
-14,254
-4% -$218K ﹤0.01% 2764
2015
Q4 		$6.29M Buy
331,758
+15,880
+5% +$303K ﹤0.01% 2705
2015
Q3 		$6M Sell
315,878
-3,156
-1% -$78.6K ﹤0.01% 2692
2015
Q2 		$8.22M Buy
319,034
+315,289
+8,419% +$8.95M ﹤0.01% 2620
2015
Q1 		$117K Sell
3,745
-256
-6% -$7.35K ﹤0.01% 3596
2014
Q4 		$154K Buy
4,001
+286
+8% +$6.83K ﹤0.01% 3543
2014
Q3 		$90K Sell
3,715
-270
-7% -$7.05K ﹤0.01% 3649
2014
Q2 		$95K Buy
3,985
+114
+3% +$3.72K ﹤0.01% 3630
2014
Q1 		$143K Buy
3,871
+470
+14% +$18.6K ﹤0.01% 3539
2013
Q4 		$137K Buy
3,401
+142
+4% +$6.03K ﹤0.01% 3524
2013
Q3 		$124K Buy
3,259
+257
+9% +$9.2K ﹤0.01% 3519
2013
Q2 		$109K Buy
+3,002
New +$129K ﹤0.01% 3507

Other funds holding PRTK

OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
IVM
InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return
AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return

BlackRock Fund Advisors's PRTK Position: Q4 2016 in Review

BlackRock Fund Advisors increased its Paratek Pharmaceuticals, Inc. (PRTK) stake by 76% in Q4 2016, buying an estimated $5.05M and bringing the position to 901,143 shares worth $13.9M. The position accounts for ﹤0.01% of the portfolio, ranked #2390.

BlackRock Fund Advisors first reported a position in PRTK in Q2 2013 and has held it in 15 quarters since. 92 funds tracked by Wall St. Rank hold PRTK as of Q4 2016.

  • BlackRock Fund Advisors held 901,143 shares of Paratek Pharmaceuticals, Inc. worth $13.9M as of Q4 2016.
  • BlackRock Fund Advisors bought 389,165 Paratek Pharmaceuticals, Inc. shares in Q4 2016, an estimated $5.05M.
  • Paratek Pharmaceuticals, Inc. made up ﹤0.01% of BlackRock Fund Advisors's portfolio in Q4 2016, its #2390 holding.
  • BlackRock Fund Advisors first reported a position in Paratek Pharmaceuticals, Inc. in Q2 2013 and has held it in 15 quarters since.
  • 92 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q4 2016.

Based on BlackRock Fund Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.